(E)-2-(2-fluoro-4-(trifluoromethyl)benzylidene)hydrazine-1-carboximidamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (E)-2-(2-fluoro-4-(trifluoromethyl)benzylidene)hydrazine-1-carboximidamide
• 英文别名: 2-[(E)-[2-fluoro-4-(trifluoromethyl)phenyl]methylideneamino]guanidine
• 化学式: C₉H₈F₄N₄
• 分子量: 248.183
• InChiKey: ASHKCLANUSUOAP-AYSLTRBKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.66
• 重原子数：
  17.0
• 可旋转键数：
  2.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  74.26
• 氢给体数：
  3.0
• 氢受体数：
  2.0

反应信息

• 作为产物：
  描述：

  肼甲酰亚胺酰胺一氯化氢 、 2-氟-4-(三氟甲基)苯甲醛 在 盐酸 作用下， 以 乙醇 为溶剂， 反应 16.0h， 以74%的产率得到(E)-2-(2-fluoro-4-(trifluoromethyl)benzylidene)hydrazine-1-carboximidamide
  参考文献：
  名称：

  不对称和单体罗布定类似物的革兰氏阳性和革兰氏阴性抗生素活性

  摘要：

  罗非替丁的去对称化（1：N '，2-二（（E）-4-氯苄叉）肼-1-羧酰亚胺肼）和亚胺烷基取代基的引入具有良好的抗生素活性。值得注意的是，两种类似物对耐万古霉素的肠球菌（VRE）的效力有所提高，其中一种的MIC为0.5μgmL -1。发现有五个类似物比铅1具有更强的效价。吲哚部分的引入导致针对甲氧西林抗性金黄色葡萄球菌（MRSA）的活性最强的robenidine类似物，MIC为1.0μgmL -1。亚胺C = NH等位基因（C = O / C = S）不活跃。单体类似物为16–64μgmL-1对MRSA和VRE有效。缺少末端酰肼NH部分的类似物在64μgmL -1下显示适度的革兰氏阴性活性。研究表明，在16–64μgmL -1下， 4-叔丁基类似物对革兰氏阳性和阴性菌株均具有活性。通常，除伴随引入亚胺C-烷基外，对芳香族基团的其他修饰耐受性差。这些类似物对MRSA和VRE的活性范围为8μgmL

  DOI：

  10.1002/cmdc.201800463

文献信息

• METHODS FOR TREATING PROTOZOAN INFECTIONS
  申请人：Neoculi Pty Ltd

  公开号：EP3188722A1

  公开（公告）日：2017-07-12
• COMPOSITIONS AND METHODS FOR MODULATING SLEEP AND WAKEFULNESS
  申请人：Chow Suk Hen

  公开号：US20150246140A1

  公开（公告）日：2015-09-03

  In some aspects, the invention relates to methods of treating conditions associated with sleep disorders, comprising administering an agent that modulates the activity of a neuropeptide receptor or a neuropeptide receptor ligand. In some aspects, the invention relates to methods of screening agents that modulate the activity of a neuropeptide receptor in an organism, optionally using cells or organisms comprising a genetic modification that affects a neuropeptide signaling pathway. In some aspects, the invention relates to methods of characterizing a condition associated with a sleep disorder comprising sequencing a nucleic acid encoding either a neuropeptide receptor or a neuropeptide receptor ligand and comparing the sequence with a reference sequence.
• [EN] METHODS FOR TREATING PROTOZOAN INFECTIONS<br/>[FR] MÉTHODES DE TRAITEMENT D'INFECTIONS À PROTOZOAIRES
  申请人：NEOCULI PTY LTD

  公开号：WO2016033635A1

  公开（公告）日：2016-03-10

  The invention provides compounds of Formula (I), and their use in methods for treating or preventing a protozoan infection in a subject using a compound of Formula (I). The invention also provides the use of a compound of Formula (I) in the manufacture of a medicament for the treatment of a protozoan infection in a subject. The invention further provides a medical device when used in a method of treating or preventing a protozoan infection in a subject and to a medical device comprising the composition of the invention.